Abstract: Interleukin-6 (IL-6) is a proinflammatory cytokine that combines IL-6 receptor (IL-6R) on cells surface and soluble IL-6R(sIL-6R) as well to activate various signaling pathways. It participates the pathophysiological processes of various skin diseases by regulating the proliferation, differentiation and function of inflammatory cells. In recent years, IL-6/IL-6R inhibitors, especially Tocilizuma has been used to treat skin diseases such as systemic sclerosis, adult-onset still’s disease, Bechet’s Disease, systemic lupus erythematosus, psoriatic arthritis, atopic dermatitis and so on. We here briefly outlined the signaling pathway and reviewed the efficacy and safety of Tocilizuma reported in clinical trials and case studies, to highlight a promising therapeutic option for some refractory immune related skin diseases.

Key words: interleukin-6')">">interleukin-6, biological agent, skin disease, tocilizumab